CompletedNCT05867732DSDCUpdated May 22, 2023

A Multicenter Observational Cohort of Degenerative Spine Diseases in China（DSDC）

An observational study in Degenerative Spine Diseases, sponsored by Xiamen University. Completed at 1 site in China. Per ClinicalTrials.gov, last updated 2023-05-22.

Sponsored by Xiamen University · Observational

Study type: Observational
Model: Cohort
Time perspective: Other
Enrollment: 10,000
Sex: All

Study summary

Study type: The objectives of this observational study were to understand, analyze, and compare the treatment and prognosis of patients with degenerative spine diseases and to construct a risk warning model and an assisted decision-making system

The main questions it aims to answer are:

[question 1] to construct a database of patients with degenerative spinal diseases and to study their associated prognosis, complications, and other risks
[Question 2] Use big data to build a risk early warning model and assisted decision making system The study will not intervene with patients

Conditions studied

Degenerative Spine Diseases

Browse trials for

Spinal Diseases 267

In context

Spinal Diseases

267 studies on the registry are indexed under Spinal Diseases; 54 are open to participants now.

This study's enrollment of 10,000 is above the median of 108 across 87 observational studies indexed under Spinal Diseases.

Browse Spinal Diseases studies →

Lead sponsor

Xiamen University is the lead sponsor of 26 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible: All
Accepts healthy volunteers: No
Sampling method: Non-probability sample

Study population

Patients with degenerative spine disease (lumbar disc herniation, lumbar spinal stenosis, lumbar spondylolisthesis, scoliosis deformity, etc.) seen and treated in participating units between January 2015 and January 2022, excluding patients with neoplastic disease

Inclusion criteria

patients with degenerative spine disease admitted to the units participating in the study from January 2015 to mid-January 2022;
complete patient data with no more than 5% missing;

Exclusion criteria

Exclusion Criteria:

Patients with oncology;

Study design

Observational model: Cohort
Time perspective: Other
Enrollment: 10,000 participants (actual)
Target follow-up: 1 Year
Patient registry: Yes

What researchers measure

Primary outcomes

Collect demographics (Hospital Information System)
Collect demographics from the HIS system for patients with degenerative spine disease
Time frame: 2022.03

Study locations

1 site

Wenle Li
Xianmen, 361102, China

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on May 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT05867732
Lead sponsor: Xiamen University
Responsible party: Wenle Li (Dr., Xiamen University) — Principal investigator
First posted: May 22, 2023
Start date: Mar 1, 2022
Primary completion: Mar 10, 2022
Completion: Mar 1, 2023
Last update: May 22, 2023

Study contacts

Wenle Wenle, M.D.

principal investigator · Xiamen University

Oversight

Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Spinal Diseases→

Other studies from this sponsor

Xiamen University

Start the discussion